First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report
In acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), neonatal Fc-receptor (FcRn) inhibition has broadened the therapeutic spectrum. Myasthenic crisis (MC), heralded by an impending myasthenic crisis (iMC), is a critical condition requiring treatments with rapid ons...
Saved in:
| Main Authors: | Isabelle Kwiedor, Martina Menacher, Monika Ellßel, Markus Naumann, Antonios Bayas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864241307687 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Complement inhibition in seropositive generalized myasthenia gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis—a case series
by: Martina Menacher, et al.
Published: (2024-12-01) -
Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis
by: Jing Ma, et al.
Published: (2024-11-01) -
Case report: Successful perioperative intervention with efgartigimod in a patient in myasthenic crisis
by: Shahar Shelly
Published: (2025-01-01) -
Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants
by: Shan Jing, et al.
Published: (2024-10-01) -
Pulmonary Edema in Myasthenic Crisis
by: Uttara Swati Anand, et al.
Published: (2013-01-01)